KPH Healthcare Services, Inc. v. Mylan N.V.

District Court, D. Kansas·Decided August 20, 2024·No. 2:20-cv-02065·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

KPH HEALTHCARE SERVICES, INC., a/k/a KINNEY DRUGS INC., FWK HOLDINGS LLC, and CESAR CASTILLO, LLC, individually and on behalf of all others similarly Case No. 2:20-cv-2065-DDC-TJJ situated,

Plaintiffs,

v.

MYLAN N.S., MYLAN SPECIALTY L.P., MYLAN PHARMACEUTICALS, INC.,

Defendants. ____________________________________

MEMORANDUM AND ORDER This matter is before the Court on Plaintiffs’ Motion to Compel (ECF No. 421). Plaintiffs seek an order requiring Defendants Mylan, N.V., Mylan Pharmaceuticals Inc., and Mylan Specialty L.P. (“the Mylan Defendants”) to produce documents improperly withheld pursuant to the Mylan Defendants’ amended privilege log and to produce documents responsive to Request for Production (“RFP”) Nos. 19 and 21. The Mylan Defendants oppose the motion, arguing the motion is untimely under D. Kan. Rule 37.1(c), the documents on the privilege log were properly withheld, and RFP Nos. 19 and 21 are not relevant. As set forth below, the Court denies Plaintiffs’ motion, although with regard to the amended privilege log, the motion is denied without prejudice as discussed below. I. Relevant Background This case arises out of the manufacture and sale of the Epi-Pen—an epinephrine auto- injection (“EAI”) drug device used to treat anaphylaxis. Plaintiffs bring this lawsuit on behalf of themselves and a putative class of direct purchasers of the Epi-Pen. Generally, Plaintiffs assert that Defendants engaged in unlawful monopolization of the EAI market, violating Sections 1 and 2 of

the Sherman Act, 15 U.S.C. §§ 1, 2, and Section 3 of the Clayton Act, 15 U.S.C. § 14. A. RFP Nos. 19 and 21 On March 14, 2024, the Mylan Defendants served their objections to five new document requests served by Plaintiffs, including RFP Nos. 19 and 21. RFP No. 19 requests all documents concerning any agreement entered into between the Mylan Defendants and Teva on or about June 8, 2012, with respect to generic modafinil (Provigil tablets), and RFP No. 21 requests all documents concerning the Generic Epinephrine Auto-Injector Handling Study. On March 22, 2024, Plaintiffs asked to meet and confer regarding the Mylan Defendants’ objections. On March 28, April 17, and April 23, 2024, the parties met and conferred to discuss their positions and

exchange arguments. On May 10, 2024, the Mylan Defendants stated their position in writing by letter, expressly stating they were “stand[ing] on their objection” to RFP No. 19. On May 21, 2024, Plaintiffs responded by withdrawing three of the requests but providing arguments supporting the relevance of RFP Nos. 19 and 21. The Mylan Defendants did not respond to the May 21, 2024, letter as the parties continued to confer regarding schedule extensions, an expert stipulation, production of previously required transitional data, scheduling depositions, a discovery plan, and the privilege log. On July 23, 2024, Plaintiffs inquired of the Mylan Defendants’ response to the May 21, 2024, letter. The Mylan Defendants stated they had no intention of responding. On July 29, 2024, Plaintiffs contacted the Court requesting a Rule 37.1 pre-motion conference. 2 B. Privilege Log The Mylan Defendants objected to Plaintiffs’ discovery requests in part on attorney-client privilege grounds. On December 15, 2023, Plaintiffs asked the Mylan Defendants to produce a privilege log required by Federal Rule of Civil Procedure 26(b)(5) for their court-ordered document production. More than three months later, on March 26, 2024, the Mylan Defendants

served a privilege log that was missing subject/title information. On April 26, 2024, Plaintiffs requested and the Mylan Defendants supplemented and amended their privilege log with 10,752 entries. Plaintiffs reviewed the privilege log, engaging lawyers at three law firms and performing approximately 178 hours of work between April 26, 2024, and June 26, 2024. On June 20, 2024, Plaintiffs had identified their concerns and advised the Mylan Defendants a letter would be forthcoming. Plaintiffs sent the Mylan Defendants a letter on June 26, 2024, identifying approximately 225 disputed documents identified on the privilege log falling into five categories. On July 17, 2024, Plaintiffs inquired regarding the Mylan Defendants’ response to the June 26, 2024, letter. The Mylan Defendants responded and stated Plaintiffs cannot raise the dispute

because their 30-day deadline under D. Kan. Local Rule 37.1(c) had passed. On July 23, 2024, the parties met via Zoom and the Mylan Defendants again refused to substantively respond. On July 24, 2024, Plaintiffs provided additional authority regarding D. Kan. Rule 37.1(c), and on July 29, 2024, Plaintiffs contacted the Court requesting a Rule 37.1(a) pre-motion conference. On August 1, 2024, the Court held a hearing to discuss the issue of timeliness under the amended Local Rule and indicated it would need briefing on the issue.

3 II. Legal Standard A magistrate judge is “afforded broad discretion in the resolution of nondispositive discovery disputes.”1 Federal Rule of Civil Procedure 37(a)(3)(B) permits a party seeking discovery to move for an order compelling an answer, designation, production, or inspection. The motion may be made if a party fails to produce documents as requested under Rule 34.2 An evasive

or incomplete disclosure, answer, or response is treated as a failure to disclose, answer, or respond.3 D. Kan. Rule 37.1(c) governs the time for filing discovery-related motions. It states: Any discovery-related motion must be filed within 30 days of the default or service of the response, objection, or disclosure that is the subject of the motion, or, for all other disputes, within 30 days after the movant knew or reasonably should have known of the potential dispute. The court may deny any motion filed after that 30- day period as untimely unless the movant demonstrates diligence in attempting to resolve the specific discovery dispute at issue.4

The purpose of this rule “is to ensure the court can address discovery disputes while they are still fresh, and in turn expedite litigation.”5 The Court will then apply a two-pronged inquiry: (1) whether the discovery motion was filed within the 30-day period, and (2) whether the moving

1 Smith v. MCI Telecomms. Corp., 137 F.R.D. 25, 27 (D. Kan. 1991).

2 Fed. R. Civ. P. 37(a)(3)(B)(iv).

3 Fed. R. Civ. P. 37(a)(4).

4 D. Kan. Rule 37.1(c) (the rule was amended effective December of 2022). Prior to the amendment, the rule required any motion to compel discovery to be “filed and served within 30 days of the default or service of the response, answer, or objection that is the subject of the motion. . . . Otherwise, the objection to the default, response, answer, or objection is deemed waived.”

5 Grider v. Shawnee Mission Med. Ctr., Inc., No. 16-2750-DDC-GLR, 2018 WL 2225011, at *1 (D. Kan. May 15, 2018).

4 party exercised diligence in attempting to resolve the discovery dispute to warrant an extension of that period.6 “The Court will not entertain any motion to resolve a discovery dispute pursuant to Fed. R. Civ. P. 26 through 37, . . .

Free access — add to your briefcase to read the full text and ask questions with AI

KPH Healthcare Services, Inc. v. Mylan N.V., (D. Kan. 2024).

KPH Healthcare Services, Inc. v. Mylan N.V. (KPH Healthcare Services, Inc. v. Mylan N.V.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Benavidez v. Sandia National Laboratories
319 F.R.D. 696 (D. New Mexico, 2017)
Smith v. MCI Telecommunications Corp.
137 F.R.D. 25 (D. Kansas, 1991)